Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.025 | 0.7 |